JEMPERLI

This brand name is authorized in Estonia, Finland, Ireland, Israel, Lithuania, Poland

Active ingredients

The drug JEMPERLI contains one active pharmaceutical ingredient (API):

1 Dostarlimab
UNII P0GVQ9A4S5 - DOSTARLIMAB

Dostarlimab is a humanised mAb of the IgG4 isotype that binds to PD-1 receptors and blocks the interactions of binding with its ligands PD-L1 and PD-L2. The inhibition of PD-1 pathway-mediated immune response results in inhibition of T-cell function such as proliferation, cytokine production, and cytotoxic activity. Dostarlimab potentiates T-cell responses, including anti-tumour immuno responses through blockade of PD-1 binding to PD-L1 and PD-L2.

Read about Dostarlimab

Medication package inserts

Below package inserts are available for further reading:

Title Information Source Document Type  
JEMPERLI Concentrate for solution for infusion European Medicines Agency (EU) MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
L01FF07 Dostarlimab L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01F Monoclonal antibodies and antibody drug conjugates → L01FF PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors
Discover more medicines within L01FF07

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: EE Ravimiamet Identifier(s): 1847314
Country: FI Lääkealan turvallisuus- ja kehittämiskeskus Identifier(s): 452871
Country: IL מִשְׂרַד הַבְּרִיאוּת Identifier(s): 9019
Country: LT Valstybinė vaistų kontrolės tarnyba Identifier(s): 1092482
Country: PL Rejestru Produktów Leczniczych Identifier(s): 100448832

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.